ATR-101 free base

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM; induces H295R cell apoptosis.

ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM; induces H295R cell apoptosis, causes mitochondrial hyperpolarization, reactive oxygen release, and ATP depletion, caspase-3/7 activation, and membrane permeabilization; decreases the formation of cholesteryl esters and increases FC levels in H295R adrenocortical carcinoma cells; inhibits the establishment and impeds the growth of ACC-derived H295R cell xenografts in mice; orally active.Cushing Disease Phase 2 Clinical

ATR101;Nevanimibe;PD-132301

Others

Other Targets

Other Targets

Endocrinology

Cushing Disease

133825-80-6

421.63

C27H39N3O

>98% (HPLC)

——

O=C(NCC1(C2=CC=C(N(C)C)C=C2)CCCC1)NC3=C(C(C)C)C=CC=C3C(C)C

1-(2,6-diisopropylphenyl)-3-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea

(-20℃)

With Ice Pack

≥ 2 years